e-learning
resources
2019
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Systemic biomarkers in electronic cigarette users: implications for noninvasive assessment of vaping-associated pulmonary injuries
Kameshwar P. Singh, Gina Lawyer, Thivanka Muthumalage, Krishna P. Maremanda, Naushad Ahmad Khan, Samantha R. McDonough, Dongxia Ye, Scott McIntosh, Irfan Rahman
Source:
ERJ Open Res, 5 (4) 00182-2019; 10.1183/23120541.00182-2019
Journal Issue:
October
Disease area:
Airway diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kameshwar P. Singh, Gina Lawyer, Thivanka Muthumalage, Krishna P. Maremanda, Naushad Ahmad Khan, Samantha R. McDonough, Dongxia Ye, Scott McIntosh, Irfan Rahman. Systemic biomarkers in electronic cigarette users: implications for noninvasive assessment of vaping-associated pulmonary injuries. ERJ Open Res, 5 (4) 00182-2019; 10.1183/23120541.00182-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Definition and history of sarcoidosis
Evidence of early abnormal airways’ inflammation in children with type 1 diabetes
Related content which might interest you:
Noninvasive assessment in the evaluation of occupational lung diseases
Source: Annual Congress 2009 - MP8 - Noninvasive assessment in the evaluation of occupational lung diseases
Year: 2009
Risk stratification of pulmonary embolism: clinical evaluation, biomarkers or both?
Source: Eur Respir J 2015; 46: 1551-1553
Year: 2015
Are FENO indices useful diagnostic tools in suspected asthma? Experience of a routine lung function laboratory
Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers
Year: 2011
Evaluation of recently validated non-invasive formula using basic lung functions as a new screening tool for pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009
Smoking cessation: a critical investigative tool in COPD
Source: Eur Respir J 2006; 27: 860-861
Year: 2006
Current clinical management of smoke inhalation injuries: a reality check
Source: Eur Respir J, 52 (6) 1802163; 10.1183/13993003.02163-2018
Year: 2018
Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice
Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019
Year: 2020
Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice
Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies
Year: 2009
Distance assessment of the risk of pulmonary hypertension associated with connective tissue diseases: do biomarkers help?
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
New potential diagnostic biomarkers for pulmonary hypertension
Source: Eur Respir J 2015; 46: 1390-1396
Year: 2015
Serial FEV1 measurements: an improved diagnostic tool for occupational asthma?
Source: International Congress 2017 – Asthma: clinical and epidemiologic characterisation
Year: 2017
The clinical role of routine non-invasive parameters in the diagnostic work-up of patients with risk for pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models
Year: 2012
Pulmonary hypertension and COPD: Clinical assessment and biomarkers
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II
Year: 2013
Screening pulmonary hypertension by lung doppler signal: A proof-of-concept study
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Is it time for home treatment of pulmonary embolism
Source: Eur Respir J 2012; 40: 742-749
Year: 2012
Clinical applications of electronic monitoring - potential and pitfalls
Source: Annual Congress 2005 - Practical and scientific considerations in the use of new electronic technologies for ambulatory monitoring of respiratory disease
Year: 2005
Role of biomarkers in the assessment and phenotyping asthma and COPD
Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases
Year: 2017
Comparison of risk assessment strategies for not-high-risk pulmonary embolism
Source: Eur Respir J 2016; 47: 1170-1178
Year: 2016
Gamma-Glutamyltransferase in pulmonary hypertension: A reliable biomarker?
Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept